ArticleeLife2021
USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.The journal of pathology. Clinical research · 2022Pooled it
- Development of XYD113 as a potent and highly selective GSPT1 degrader for cancer therapy.Acta pharmacologica Sinica · 2026Article
- Balancing Ubiquitination and Deubiquitination in Apoptotic Protein Stability and Cancer Cell Survival.International journal of molecular sciences · 2026Review
- Structure Merging Approach Leads to New Dual Potent and Selective USP25/USP28 Inhibitors.Journal of medicinal chemistry · 2026Article
- Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer.The EMBO journal · 2026Article
- Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance.Discover oncology · 2026Review
- Ubiquitin-specific protease 25: a new regulator for cardiovascular and cerebrovascular diseases.Frontiers in cell and developmental biology · 2026Review
- Pathological role of deubiquitinating enzymes in lung cancer: recent insights and advances.American journal of cancer research · 2026Review
- Targeting the deubiquitinase USP28 in cancer: navigating context-dependent mechanisms and therapeutic resistance.Frontiers in immunology · 2026Review
- Pharmacologic interrogation of USP28 cellular function in p53 signaling.Cell chemical biology · 2025Article
- Article
- USP28 promotes PARP inhibitor resistance by enhancing SOX9-mediated DNA damage repair in ovarian cancer.Cell death & disease · 2025Article
- Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck.Nature reviews. Clinical oncology · 2025Review
- Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects.Biomolecules · 2025Review
- TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Deubiquitinating enzyme USP28 inhibitor AZ1 alone and in combination with cisplatin for the treatment of non-small cell lung cancer.Apoptosis : an international journal on programmed cell death · 2024Article
- Structural basis for the bi-specificity of USP25 and USP28 inhibitors.EMBO reports · 2024Article
- LINC01133 regulates MARCKS expression via sponging miR-30d-5p to promote the development of lung squamous cell carcinoma.Translational oncology · 2024Article
- Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis.Acta pharmaceutica Sinica. B · 2024Article
- Landscape of targeted therapies for lung squamous cell carcinoma.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 7 institutions in 4 countries.
E Josue RuizAdult stem cell laboratory, The Francis Crick Institute, London, United Kingdom.
Adan Pinto-FernandezTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-1693-9664
Andrew P TurnbullLondon Bioscience Innovation Centre, CRUK Therapeutic Discovery Laboratories, London, United Kingdom.
Linxiang LanAdult stem cell laboratory, The Francis Crick Institute, London, United Kingdom.
Thomas M CharltonTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Hannah C ScottTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Andreas DamianouTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
George VereTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-1154-5212
Eva M RiisingAdult stem cell laboratory, The Francis Crick Institute, London, United Kingdom.
Clive Da CostaAdult stem cell laboratory, The Francis Crick Institute, London, United Kingdom.
Wojciech W KrajewskiLondon Bioscience Innovation Centre, CRUK Therapeutic Discovery Laboratories, London, United Kingdom.
David GuerinFORMA Therapeutics, Watertown, United Kingdom.
Jeffrey D KearnsFORMA Therapeutics, Watertown, United Kingdom.ORCID 0000-0001-7261-5096
Stephanos IoannidisFORMA Therapeutics, Watertown, United Kingdom.
Marie KatzFORMA Therapeutics, Watertown, United Kingdom.
Crystal McKinnonFORMA Therapeutics, Watertown, United Kingdom.
Jonathan O'ConnellFORMA Therapeutics, Watertown, United Kingdom.
Natalia MoncautGenetic Manipulation Service, The Francis Crick Institute, London, United States.
Ian RosewellGenetic Manipulation Service, The Francis Crick Institute, London, United States.
Emma NyeAdult stem cell laboratory, The Francis Crick Institute, London, United Kingdom.
Neil JonesLondon Bioscience Innovation Centre, CRUK Therapeutic Discovery Laboratories, London, United Kingdom.
Claire HerideLondon Bioscience Innovation Centre, CRUK Therapeutic Discovery Laboratories, London, United Kingdom.ORCID 0000-0003-1927-9577
Malte GerschMax Planck Institute of Molecular Physiology, Dortmund, Germany.
Min WuFORMA Therapeutics, Watertown, United Kingdom.
Christopher J DinsmoreFORMA Therapeutics, Watertown, United Kingdom.
Tim R HammondsLondon Bioscience Innovation Centre, CRUK Therapeutic Discovery Laboratories, London, United Kingdom.
Sunkyu KimIncyte, Wilmington, United States.
David KomanderUbiquitin Signalling Division, Walter and Eliza Hall Institute of Medical Research, Royal Parade, and Department of Medical Biology, University of Melbourne, Melbourne, Australia.
Sylvie UrbeCellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
Michael J ClagueCellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.ORCID 0000-0003-3355-9479
Benedikt M KesslerTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-8160-2446
Axel BehrensAdult stem cell laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-1557-1143
Forma Therapeutics (United States) · USThe Francis Crick Institute · GBTarget (United States) · USUniversity of Liverpool · GBIncyte (United States) · USMax Planck Institute of Molecular Physiology · DEThe University of Melbourne · AU
Funding
Cancer Research UK FC001039Wellcome Trust 097813/Z/11/ZWellcome Trust FC001039
Abstract
Lung squamous cell carcinoma (LSCC) is a considerable global health burden, with an incidence of over 600,000 cases per year. Treatment options are limited, and patient's 5-year survival rate is less than 5%. The ubiquitin-specific protease 28 (USP28) has been implicated in tumourigenesis through its stabilization of the oncoproteins c-MYC, c-JUN, and Δp63. Here, we show that genetic inactivation of
Indexed as
Gene DeletionAnimalsDisease Models, AnimalDNA-Binding ProteinsHumansLung NeoplasmsMiceNeoplasms, Squamous CellTranscription FactorsUbiquitin ThiolesteraseDNA-Binding ProteinsMYCBP protein, humanTranscription FactorsUbiquitin ThiolesteraseUSP28 protein, mousebiochemistrycancer biologychemical biologyc-MYChumansquamous cell lung cancerUSP28
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.